drugset / Trial / NCT05280314
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Phase 2
Recruiting
60 enrolled
IO Biotech
Almac · collabMerck Sharp & Dohme LLC · collabTheradex · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, multi-arm trial evaluating anti-tumor activity, safety, and immune infiltration of IO102-IO103 in combination with pembrolizumab KEYTRUDA® as neoadjuvant and post-surgery treatment. This proof-of-concept trial will include patients with resectable tumors in at least 2 indications.
Timeline
- Start
- 2023-12-21
- Primary completion
- 2025-04-30
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMSAPEPIMUT | Peptide | 85 ug | Subcutaneous |
| Subject | IO103 | Vaccine | 85 ug | Subcutaneous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |